Editorial · Longevity · NAD+
NR vs NMN: the precursor comparison
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Published Mon Jun 01 2026 01:00:00 GMT+0100 (British Summer Time) · 5 min read
NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are the two NAD+ precursors that dominate the supplement market. Both are converted to NAD+ inside cells, by slightly different routes, and both have human trials showing they raise blood NAD+ markers and are generally well tolerated over studied periods. The clearest practical difference is regulatory history: NR, often sold as Niagen, has a more settled food-supplement status, while NMN's novel-food position in the UK and EU has been in flux. Neither is proven to reverse ageing. This is editorial, not medical advice.
If you have already worked out that NAD+ supplements really mean precursor supplements, the next question is which precursor: NR or NMN. This post compares the two for UK readers. It is editorial commentary, not medical advice.
Two roads to the same molecule
Both NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are precursors that cells convert into NAD+, the end-product co-enzyme. They are chemically close: NR is, in simple terms, one step further back in the pathway, and one route of NAD+ production converts NR to NMN and then to NAD+. The headline point is that both are precursors aiming at the same target, as set out in NAD+ vs NMN and NAD+ supplements in the UK.
Because they are so closely related, the differences that matter to a shopper are less about biology and more about evidence maturity and regulation.
What the evidence shows
Both precursors have human trials behind them. Across those studies, both NR and NMN are reported to raise blood NAD+ markers and to be generally well tolerated over the periods studied. NR, marketed for longer (often under the Niagen brand), has accumulated a somewhat larger published human trial base simply because it has been on the market longer. NMN has attracted intense research and consumer interest, partly on the back of widely publicised animal work.
The crucial caveat applies equally to both: raising an NAD+ marker is not the same as a proven health outcome. Studies suggest both precursors do what a precursor should; studies do not establish that either reverses ageing or treats a condition, and there are no large long-term randomised trials confirming the headline claims for either.
The clearest difference: regulatory history
For a UK shopper, the most concrete distinction is regulatory. NR has a more settled food-supplement history and is stocked routinely at larger UK health retailers. NMN’s status has been more eventful: it remains legal to sell in the UK as a food supplement, EFSA has issued a positive safety opinion, and it is not yet formally authorised as a novel food in the EU, a position that has shifted since 2022 and is still moving. We track that on the NMN sub-hub.
In plain terms: both are available in the UK, but NR sits on more settled regulatory ground, while NMN carries an evolving novel-food question in the background.
How to choose
There is no evidence base that lets anyone crown one precursor a clear winner on outcomes, so the choice tends to come down to availability, transparency and the regulatory comfort you want. The label checklist in best NAD+ supplement UK applies to either. We do not state doses; what studies have used is described in general terms in the linked posts, alongside the framing that supplement decisions should be discussed with a suitably qualified healthcare professional.
Read next
The NAD+ sub-hub maps every route, and the NMN sub-hub goes deeper on the most-discussed precursor. For the bigger picture, see NAD+ in the UK: the landscape explained.